Overactive Bladder Therapeutics Market

Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Overactive Bladder Therapeutics Market contains market size and forecasts of Overactive Bladder (OAB) Therapeutics in global, including the following market information:
Global Overactive Bladder (OAB) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Overactive Bladder (OAB) Therapeutics Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Overactive Bladder (OAB) Therapeutics companies in 2021 (%)
The global Overactive Bladder (OAB) Therapeutics market was valued at 3287 million in 2021 and is projected to reach US$ 3666.6 million by 2028, at a CAGR of 1.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anticholinergic Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Overactive Bladder (OAB) Therapeutics include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical and Lanzhou Institute of Biological Products, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Overactive Bladder (OAB) Therapeutics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Overactive Bladder (OAB) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Overactive Bladder (OAB) Therapeutics Market Segment Percentages, by Type, 2021 (%)
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Global Overactive Bladder (OAB) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Overactive Bladder (OAB) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hosptial
Clinci
Other
Global Overactive Bladder (OAB) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Overactive Bladder (OAB) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Overactive Bladder (OAB) Therapeutics revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Overactive Bladder (OAB) Therapeutics revenues share in global market, 2021 (%)
Key companies Overactive Bladder (OAB) Therapeutics sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Overactive Bladder (OAB) Therapeutics sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries